Equities analysts forecast that Eidos Therapeutics Inc (NASDAQ:EIDX) will report earnings per share (EPS) of ($0.28) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Eidos Therapeutics’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.30). The firm is scheduled to announce its next earnings report on Tuesday, February 5th.

According to Zacks, analysts expect that Eidos Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.17) to ($1.78). For the next year, analysts anticipate that the firm will post earnings of ($1.31) per share, with EPS estimates ranging from ($1.50) to ($0.98). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Eidos Therapeutics.

Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.02).

A number of research analysts recently commented on the company. Zacks Investment Research cut Eidos Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 17th. Roth Capital assumed coverage on Eidos Therapeutics in a report on Wednesday, October 31st. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Bank of America lowered their price target on Eidos Therapeutics from $24.00 to $13.00 and set a “neutral” rating on the stock in a report on Monday, October 1st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $27.25.

NASDAQ EIDX traded up $0.48 during trading hours on Thursday, reaching $14.22. The company’s stock had a trading volume of 125,400 shares, compared to its average volume of 160,918. Eidos Therapeutics has a 1 year low of $8.89 and a 1 year high of $24.75.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Flinton Capital Management LLC purchased a new stake in shares of Eidos Therapeutics during the 2nd quarter worth approximately $110,000. Point72 Hong Kong Ltd purchased a new stake in shares of Eidos Therapeutics during the 2nd quarter worth approximately $111,000. Bank of New York Mellon Corp purchased a new stake in shares of Eidos Therapeutics during the 3rd quarter worth approximately $137,000. Tiverton Asset Management LLC purchased a new stake in shares of Eidos Therapeutics during the 2nd quarter worth approximately $163,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Eidos Therapeutics during the 3rd quarter worth approximately $167,000. 22.99% of the stock is currently owned by institutional investors.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Further Reading: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.